IL2 and acute myeloid leukemia: Initial studies showed that haploidentical, donor-related NK cells (2 × 107 cells/Kg) infused to R/R AML patients after intensive lymphodepleting chemotherapy (cyclophosphamide and fludarabine) resulted in in vivo infusion of NK cells and remission in 5 out 19 patients; all patients received subcutaneous IL-2 administration after cell infusion [30].